Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of disease-free survival (DFS). The data suggests there is no association between an elevated level of C-reactive protein (CRP) and DFS. Results were presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now